Sonoma signs 20-year exclusive license & distribution deal with Dyamed for four Southeast Asian markets

Sonoma Pharmaceuticals, Inc.

Exclusive rights for hypochlorous acid products (dermatology, eye, oral) in Singapore, Malaysia, Indonesia, and Thailand.
20-year term; Dyamed pays royalty and transfer prices (amounts redacted).
Minimum annual purchase commitments in USD for first 10 years (redacted).
Exclusive license to use Sonoma's Microcyn trademark in the Territory.
Dyamed responsible for regulatory approvals, marketing, and distribution at its own cost.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.